Location Availability

Hospital Affiliation

Northside Hospital, Northside Hospital-Cherokee and Northside Hospital-Forsyth

Dr. Steis is a board-certified medical oncologist with expertise in treating solid tumors and blood cancers.  He completed training in internal medicine at the University of Pittsburgh and was a fellow at the National Cancer Institute and National Institutes of Health.

Dr. Steis was the Chief of the Clinical Research Branch of the NCI and he has served as the Principle Investigator for multiple cancer clinical trials.  He is a member of the Northside Hospital Melanoma Research Work Group. Dr. Steis is past-Chairman/President of the Atlanta Cancer Care Foundation.

Assisted By


Board Certifications: Internal Medicine, Medical Oncology and Hematology

Clinical Fellowship: National Cancer Institute and National Institutes of Health

Internship and Residency: University of Pittsburgh

Medical School: M.D., University of Pittsburgh, 1978

Graduate School: M.S., Biochemistry, University of Pittsburgh, 1977

Undergraduate: B.S., Summa Cum Laude, University of Pittsburgh, 1973

Hospital Affiliations: Northside Hospital, Northside Forsyth Hospital and Northside Cherokee Hospital

Education & Training


National Cancer Institute (NCI) and National Institutes of Health (NIH)


University of Pittsburgh Medical School

Medical School

University of Pittsburgh School of Medicine

Research & Clinical Trials

Dr. Steis has been the Principle Investigator (PI) for many clinical trials. He currently is the PI for:

  • A randomized, double-blind phase 2/3 study of Relatlimab combined with Nivolumab versus Nivolumab in participants with previously untreated metastatic or unresectable melanoma. www.clinicaltrials.gov/ct2/show/NCT03470922

Professional Memberships

  • Georgia Society of Clinical Oncology


Dr. Steis has authored articles that were published in the New England Journal of Medicine and the Journal of Clinical Oncology and Blood.  This is his most recent publication:

  • O’Shaughnessy, J, DeMichele, A., Ma, C.X. et al. 6.  A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.  Breast Cancer Res Treat (2018). doi.org/10.1007/s10549-018-4770-6.

Clinical Interests

  • melanoma, lymphoma, lung, colorectal, and prostate cancers

Honors & Awards

  • Voted “TOP DOC” twice by Atlanta Magazine

Find a physician